NTRA•businesswire•
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
Summary
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place January 8-10, 2026. A new analysis will be presented from the randomized, double-blind, phase III ALTAIR clinical trial (NCT04457297). ALTAIR examined treatment on molecular recurrence (TOMR) with Trifl
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 6, 2026 by businesswire